Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.68 |
| ▸ | CD44 | P16070 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440219 | 0.97 | — | — | |
| SCHEMBL28788726 | 0.97 | CYP3A4 (0.72) | CYP3A4TSHRPIK3CACD44TDP1 | |
| SCHEMBL15024 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL3429803 | 0.94 | CYP3A4 (0.68) | CYP3A4TSHRPIK3CACD44TDP1 | |
| Ammonia Solution, Strong SCHEMBL8460462 | 0.94 | CYP3A4 (0.68) | CYP3A4TSHRPIK3CACD44TDP1 | |
| Hydrochloric Acid SCHEMBL2188812 | 0.94 | CYP3A4 (0.68) | CYP3A4TSHRPIK3CACD44TDP1 | |
| Hydrochloric Acid SCHEMBL6098611 | 0.94 | CYP3A4 (0.68) | CYP3A4TSHRPIK3CACD44TDP1 | |
| Hydrochloric Acid SCHEMBL154815 | 0.94 | CYP3A4 (0.68) | CYP3A4TSHRPIK3CACD44TDP1 | |
| SCHEMBL8218942 | 0.94 | — | — | |
| Benzene SCHEMBL29109286 | 0.94 | CYP3A4 (0.68) | CYP3A4TSHRPIK3CACD44TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118098835-A | Electrolyte additive, electrolyte containing electrolyte additive and supercapacitor | 深圳市今朝时代股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-0461597-B1 | Method for preparing monohalogenosilanes | SHINETSU CHEMICAL CO (JP) | 1995-03-01 | — | — | EP | claimed |
| EP-0461597-A2 | Method for preparing monohalogenosilanes | Shin-Etsu Chemical Co., Ltd. (JP) | 1991-12-18 | — | — | EP | claimed |
| EP-4506340-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | Obshestvo s Ogranichennoj Otvetstvennostju "Vikzdorove Zhivotnyh" (RU) | 2025-02-12 | — | — | EP | disclosed |
| US-20250026705-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | OBSHESTVO S OGRANICHENNOI OTVETSTVENNOSTIU "VIK-ZDOROVE ZHIVOTNYKH" (RU) | 2025-01-23 | — | — | US | disclosed |
| CN-118098835-A | Electrolyte additive, electrolyte containing electrolyte additive and supercapacitor | 深圳市今朝时代股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117295718-A | Method for preparing medetomidine and derivative thereof | 维科-兹多洛夫希沃特尼赫有限责任公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023182903-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | Общество с ограниченной ответственностью "ВИК-здоровье животных" | 2023-09-28 | — | — | WO | disclosed |
| CN-115768351-A | Fluid characterization method | 新生代吉恩公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115066207-A | Method and system for menses group analysis | 新生代吉恩公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-110087704-B | Anti-infective drug outflow device | 心脏起搏器股份公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-0610515-A1 | PROCESS FOR PRODUCING POLYMER | NIPPON SHOKUBAI CO., LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0461597-A2 | Method for preparing monohalogenosilanes | Shin-Etsu Chemical Co., Ltd. (JP) | 1991-12-18 | — | — | EP | disclosed |
| EP-0032062-B2 | HIGH-MOLECULAR-WEIGHT NOVOLAK SUBSTITUTED PHENOLIC RESINS AND THEIR PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-16 | — | — | EP | disclosed |
| EP-0032062-B1 | HIGH-MOLECULAR-WEIGHT NOVOLAK SUBSTITUTED PHENOLIC RESINS AND THEIR PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1985-04-03 | — | — | EP | disclosed |
| US-4331684-A | ARALKYL ESTERS OF AMINO ACIDS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1982-05-25 | — | — | US | disclosed |
| EP-0032062-A2 | High-molecular-weight novolak substituted phenolic resins and their preparation | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1981-07-15 | — | — | EP | disclosed |
| US-4237311-A | ANTIDEPRESSANTS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1980-12-02 | — | — | US | disclosed |
| US-4165322-A | 3-(ALKYL-, ALKOXY-, HALO-, OR NITRO-SUBSTITUTED)PHENYLAMINO-GAMMA-BUTYROLACTONE OR BUTYROTHIOLACTONE | CHEVRON RESEARCH COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4113736-A | NONTOXIC POLYMER STABILIZERS | S. A. LABAZ (BE) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026705-A1 | METHOD FOR PRODUCING MEDETOMIDINE AND ITS DERIVATIVES | ADRB2, OPRM1, ADRA2C | ACHE 308/4885CYP3A4 19/4885TSHR 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.